Willingness-to-pay to prevent Alzheimer’s disease: a contingent valuation approach
- 454 Downloads
As the prevalence of Alzheimer’s disease (AD) increases, the need to develop effective and well-tolerated pharmacotherapies for the prevention of AD is becoming increasingly important. Understanding determinants and magnitudes of individuals’ preferences for AD prevention programs is important while estimating the benefits of any new pharmacological intervention that targets the prevention of the disease. This paper applied contingent valuation, a method frequently used for economic valuation of goods or services not transacted in the markets, to estimate the willingness-to-pay (WTP) to prevent AD based on the nationally representative Health and Retirement Survey data. The WTP was associated in predictable ways with respondent characteristics. The mean estimated WTP for preventing AD is $155 per month (95 % CI $153–$157) based on interval regression. On average, a higher WTP for the prescription drug for AD prevention was reported by respondents with higher perceived risks, and greater household wealth. The findings provide useful information about determinants and the magnitude of individuals’ preferences for AD prevention drugs for healthcare payers and individual families while making decisions to prevent AD.
KeywordsAlzheimer’s disease Perceived risk Willingness-to-pay Contingent valuation method Interval regression
JEL ClassificationI18 I19
- Alzheimer’s Disease, Facts & Figures (2011). http://www.alz.org/downloads/facts_figures_2011.pdf.
- Alzheimer’s Disease, Facts & Figures (2012). http://www.alz.org/downloads/facts_figures_2012.pdf.
- Crimmins, E. M., Kim, J. K., Langa, K. M., & Weir, D. R. (2011). Assessment of cognition using surveys and neuopsychological assessment: The Health and Retirement Study and the Aging Demographics, and Memory Study. The Journals of Gerontology Series B, 66, i162–171. doi: 10.1093/geronb/gbr048.CrossRefGoogle Scholar
- Grossberg, G. T., Pejovic, V., & Miller, M. L. (2007). Current strategies for the treatment and prevention of Alzheimer’s disease. Primary Psychiatry, 14, 39–54.Google Scholar
- Hanemann, W. M., & Kanninen, B. (1999). The statistical analysis of discrete-response CV data. In I. Batemen & K. Willis (Eds.), Valuing environmental preferences. Theory and practice of the contingent valuation method in the US, EU and developing countries (pp. 302–441). Oxford University Press: Oxford.Google Scholar
- Hausman, J. A. (1983). Specification and estimation of simultaneous equation models. In: Z. Griliches & M.D. Intriligator (Eds.), Handbook of econometrics (Vol. I). North-Holland Publishing Company: Amsterdam.Google Scholar
- Langa, K.M., Kabeto, M., Weir, D. (2010). Report on race and cognitive impairment using HRS in 2010 Alzheimer’s disease facts and figures. Retrieved July 12, 2010 from http://www.alz.org/documents_custom/report_alzfactsfigures2010.pdf.
- Lewin Group (2004) Saving lives, saving money: Dividends for American investing in Alzheimer’s research. Retrieved January, 2012 from http://www.lewin.com/~/media/Lewin/Site_Sections/Publications/2867.pdf.
- McCullagh, P. (1980). Regression models for ordinal data. Journal of the Royal Statistical Society, 42, 109–142.Google Scholar
- Sloane, P. D., Zimmerman, S., Suchindran, C., Reed, P., Wang, L., Boustani, M., et al. (2002). The public health impact of Alzheimer’s disease, 2000–2050: Potential implication for treatment advances. Annual Review of Public Health, 23, 213–231. doi: 10.1146/annurev.publhealth.23.100901.140525.PubMedCrossRefGoogle Scholar
- Society of Actuaries (2012). Key findings and issues: Longevity, 2011 risks and process of retirement survey report. Retrieved January, 2013 from www.soa.org/files/research/projects/research-key-finding-longevity.pdf.
- Wooldridge, J. M. (2002). Econometric analysis of cross section and panel data. Cambridge, MA: MIT Press.Google Scholar